Syngene International Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 12.5% at ₹1.25/Share	25-Jun-2026	26-Jun-2026
DividendsFinal Dividend of 12.5% at ₹1.25/Share	27-Jun-2025	27-Jun-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Nippon India Small Cap Fund - Growth	1.33 Cr	1.33 Cr no change
ICICI Prudential Multi Cap Fund - Growth	79.51 Lac	79.51 Lac no change
SBI Multi Asset Allocation Fund - Regular Plan - Growth	70.00 Lac	70.00 Lac no change
Nippon India Multi Cap Fund - Growth	65.81 Lac	65.81 Lac no change
ICICI Prudential Healthcare Fund - Growth	57.48 Lac	65.78 Lac (14.44%)

CA Sumit Mangla

3 Sep • 1:42 PM · SEBI-Registered Analyst

Innova Captab Board OKs ₹50 Cr Land Acquisition

INNOVACAP

Board of Directors has accorded in-principle approval for the acquisition of land with an estimated investment of approximately ₹50 crore. The proposed land purchase forms part of the company’s strategic real estate expansion and plans for operational facility development. The Board will provide further updates once the final purchase or sale agreement is executed between the parties. This move aligns with Innova Captab’s broader growth strategy in the pharmaceutical manufacturing and CDMO space, aimed at supporting future capacity needs and strengthening its operational footprint. The in-principle clearance marks an important step towards enhancing the company’s long-term manufacturing and infrastructure capabilities. **Top stocks in the pharmaceuticals / CDMO industry:** Laurus Labs, Syngene International, and Divi’s Laboratories.

AALGO BREATHS I SEBI RA

16 Aug • 9:45 PM · SEBI-Registered Analyst

Syngene International Limited Latest Updates

SYNGENE

Q1 FY27 Financial Results & Net Loss On July 29, 2026, Syngene International reported its financial results for the first quarter ended June 30, 2026 (Q1 FY27). Revenue from operations declined 15.8% year-on-year to ₹736 crore (down from ₹874.5 crore in Q1 FY26). Lower operating leverage, biologics demand adjustments, and an exceptional charge of ₹13.5 crore for employee termination benefits led to a consolidated net loss of ₹9.00 crore, compared to a net profit of ₹86.70 crore in the year-ago period. Executive Leadership Transition Effective July 1, 2026, Mr. Siddharth Mittal officially took charge as the Managing Director and Chief Executive Officer (MD & CEO) of Syngene International, succeeding Peter Bains following a planned leadership transition. Alongside the CEO transition, the company appointed new commercial leadership to accelerate client outreach across the US and European contract development and manufacturing (CDMO) markets. Balance Sheet Liquidity & Cash ReservesDespite operating headwinds in Q1 FY27, Syngene maintained a conservative capital structure with a net cash reserve of ₹1,541 crore. The strong balance sheet provides financial headroom as the company manages operating expenses and continues commercial integration for its US Bayview facility and biologics development infrastructure. Technology & Research Collaborations Syngene expanded its proprietary ***** drug discovery platform, deploying gigascale virtual screening capabilities to enhance early-stage hit-finding for global pharmaceutical clients. In clinical development, the company signed a strategic Memorandum of Understanding (MoU) with the Translational Health Science and Technology Institute (BRIC-THSTI) to collaborate on early and late-phase clinical trials and translational research.

Dhwani Patel

16 Aug • 4:57 PM · SEBI-Registered Analyst

Syngene At long-term support

SYNGENE

is approaching a crucial long-term support zone at ₹360–370, which could become the base for a meaningful reversal. A sustained hold above this zone can trigger a recovery towards ₹400–410, followed by ₹493. The ₹493–510 zone is the key resistance area, while a decisive breakdown below ₹360 would weaken the reversal setup and expose lower levels.

CA Sumit Mangla

11 Aug • 9:24 PM · SEBI-Registered Analyst

Akums Guides Strong FY27 with Double-Digit CDMO Growth, 14-15% Margins

AKUMS

expects robust operating performance in FY27, with the CDMO segment maintaining double-digit volume growth and Q2 volumes in the high teens. Annual margins are guided at 14-15%, potentially towards the upper end after a strong Q1. Domestic branded formulations should improve from Q3, while international branded returns to growth. The ₹240 crore Zambia order will contribute in H2 FY27 and FY28, with European business starting in FY28. API is targeted to turn monthly EBITDA positive by end-FY27. A new Baddi facility is set to go live by year-end. Top stocks in the CDMO / pharma manufacturing industry: Syngene International, and Laurus Labs

Amit Malviya

30 Jul • 10:35 AM · SEBI-Registered Analyst

Indian markets opened choppy today (30 July 2026) with the Sensex down ~150 points and Nifty hovering near 24,240,

Indian markets opened choppy today (30 July 2026) with the Sensex down ~150 points and Nifty hovering near 24,240, as investors weighed the US Fed’s rate pause, rising crude oil prices, and renewed Middle East tensions. IT stocks are showing strength, while realty and energy counters are under pressure. Globally, Wall Street closed lower ahead of tech earnings, and Asian markets remain mixed. 📊 India Market Snapshot (30 July 2026, Morning) Sensex: 77,501.01 (↓ 153 pts, -0.20%) Nifty 50: 24,240.55 (↓ 9.65 pts, -0.04%) Key Resistance: 24,500–24,600 zone; downside support at 24,000. Sector Trends: IT stocks: Rallying, providing support. Realty stocks: Struggling to post gains. Energy stocks: Weak due to Brent crude above $90/barrel. Top Movers: Redington: Up 15% after Q1 profit surged 77%.

WAAREEENER

Waaree Energies: Down 6% post subdued Q1 results. Syngene: Down 8% after disappointing earnings. 🌍 Global Market Highlights US Federal Reserve: Held rates steady at 3.50–3.75%, but policymakers remain split on future moves. Wall Street: Closed lower; Nasdaq slipped on semiconductor weakness. Asia: Japan’s Topix fell 0.3%. Australia’s ASX 200 down 0.5%. Hong Kong’s Hang Seng flat. Shanghai Composite down 0.5%. South Korea’s Kospi continues steep declines amid AI-tech selloff. Europe: Euro Stoxx 50 futures up 0.2%. ⚠️ Key Risks & Drivers Crude Oil: Brent above $90/barrel, WTI ~$83–84, raising inflation and rupee concerns. Geopolitical Tensions: US–Iran conflict intensifies with fresh military strikes, adding risk premium to energy markets. Earnings Season: Heavy day with results from M&M, Bajaj Finance, Vedanta, Dabur, Eicher Motors, Mazagon Dock. Currency: Rupee opened stronger at 95.59/USD, supported by RBI intervention and FPI inflows.

Prameela Balakkala

29 Jul • 9:01 AM · SEBI-Registered Analyst

Market Opening Snapshot

📊 Market Opening Snapshot GIFT Nifty: 24,221 (+130 pts) → gap-up start. Sensex (Prev Close): 76,766 (–0.09%). Nifty 50 (Prev Close): 23,985 (–0.04%). Bank Nifty (Prev Close): 56,756 (–0.58%). 🌍 Global Market & Commodities US Markets: Dow +1.03%, S&P +0.21%, Nasdaq –0.22%. Asia: Nikkei –0.49%, Kospi –2.08%, Hang Seng +1.45%. Brent Crude: $87.7/barrel (↑4%). WTI Crude: $82.6/barrel (↑4%). Gold: ~$4,021/oz (↓0.3%). Silver: ~$59.9/oz (↑0.1%). Rupee: ~₹96.1/$, stable. Nifty 50 23,800–23,850 24,200–24,300 Sideways–Bullish Bank Nifty 56,400–56,600 57,300–57,500 Sideways–Bullish 📈 Derivatives & Sentiment PCR (Put-Call Ratio): Nifty ~0.92 → neutral. Max Pain: 24,000 strike. India VIX: ~12.4 → subdued volatility. 💰 Institutional Flows (July 28, 2026) FII: Net buyers +₹755 Cr. DII: Net buyers +₹1,664 Cr. Trend: FIIs cautious but turned buyers; DIIs continue strong inflows. 🏦 Stocks in Focus Results Today: Asian Paints, Dabur, Adani Enterprises, Adani Ports, Eicher Motors, Colgate-Palmolive, Piramal Pharma, Syngene, V-Guard, Zensar Tech. Brokerage Calls: CLSA retains Outperform on L&T (TP ₹4,842); Choice Broking highlights breakout stocks: eClerx, Universal Cables, Five-Star Business Finance, Mankind Pharma, Knowledge Marine. 📑 Brokerage & Expert Views Motilal Oswal: Nifty range 23,900–24,300; buy-on-dips strategy. Choice Broking (Sumeet Bagadia): Nifty consolidation; watch 23,800–23,850 support, 24,200–24,250 resistance. Religare Broking: Maintain stock-specific approach until Fed clarity. ⚠️ Risks & Watchpoints US–Iran conflict: Renewed strikes → crude surge. Fed policy decision: Expected status quo at 3.50–3.75%, but commentary key. Monsoon concerns: Below-normal rains may pressure rural demand. Heavy earnings calendar: Volatility in FMCG, infra, pharma stocks.

Syngene International Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Syngene International Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Syngene International Ltd.?

What is the market cap of Syngene International Ltd.?

Should I buy Syngene International Ltd. stock now?

What is the 52 week high and low of Syngene International Ltd.?

Is the Syngene International Ltd. stock good to buy?

Is Syngene International Ltd. a good buy for the long term?

Is Syngene International Ltd. overvalued or undervalued?

What is the PE and PB ratio of Syngene International Ltd.?